Drug discovery in focal and segmental glomerulosclerosis

Nick Pullen, Alessia Fornoni

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Despite the high medical burden experienced by patients with focal segmental glomerulosclerosis, the etiology of the condition remains largely unknown. Focal segmental glomerulosclerosis is highly heterogeneous in clinical and morphologic manifestations. While this presents challenges for the development of new treatments, research investments over the last 2 decades have yielded a surfeit of potential avenues for therapeutic intervention. The development of many of those ideas and concepts into new therapies, however, has been very disappointing. Here, we describe some of the factors that have potentially contributed to the poor translational performance from this research investment, including the confidence we ascribe to a target, the conduct of experimental studies, and the availability of selective reagents to test hypotheses. We will discuss the significance of genetic and systems traits as well as other methods for reducing bias. We will analyze the limitations of a successful drug development. We will use specific examples hoping that these will guide a consensus for investment and drive greater translational quality. We hope that this substrate will serve to exemplify the tremendous opportunity for intervention as well as facilitate greater collaborative effort between industry, academia, and private foundations in promoting appropriate validation of these targets. Only then will we have achieved our goal for curative therapies for this devastating disease.

Original languageEnglish (US)
Pages (from-to)1211-1220
Number of pages10
JournalKidney International
Volume89
Issue number6
DOIs
StatePublished - 2016

Fingerprint

Focal Segmental Glomerulosclerosis
Drug Discovery
Translational Medical Research
Therapeutics
Industry
Research
Pharmaceutical Preparations

Keywords

  • focal segmental glomerulosclerosis
  • podocyte
  • proteinuria

ASJC Scopus subject areas

  • Nephrology

Cite this

Drug discovery in focal and segmental glomerulosclerosis. / Pullen, Nick; Fornoni, Alessia.

In: Kidney International, Vol. 89, No. 6, 2016, p. 1211-1220.

Research output: Contribution to journalReview article

@article{6b74362e79b74cf7b8e82d4d8b222169,
title = "Drug discovery in focal and segmental glomerulosclerosis",
abstract = "Despite the high medical burden experienced by patients with focal segmental glomerulosclerosis, the etiology of the condition remains largely unknown. Focal segmental glomerulosclerosis is highly heterogeneous in clinical and morphologic manifestations. While this presents challenges for the development of new treatments, research investments over the last 2 decades have yielded a surfeit of potential avenues for therapeutic intervention. The development of many of those ideas and concepts into new therapies, however, has been very disappointing. Here, we describe some of the factors that have potentially contributed to the poor translational performance from this research investment, including the confidence we ascribe to a target, the conduct of experimental studies, and the availability of selective reagents to test hypotheses. We will discuss the significance of genetic and systems traits as well as other methods for reducing bias. We will analyze the limitations of a successful drug development. We will use specific examples hoping that these will guide a consensus for investment and drive greater translational quality. We hope that this substrate will serve to exemplify the tremendous opportunity for intervention as well as facilitate greater collaborative effort between industry, academia, and private foundations in promoting appropriate validation of these targets. Only then will we have achieved our goal for curative therapies for this devastating disease.",
keywords = "focal segmental glomerulosclerosis, podocyte, proteinuria",
author = "Nick Pullen and Alessia Fornoni",
year = "2016",
doi = "10.1016/j.kint.2015.12.058",
language = "English (US)",
volume = "89",
pages = "1211--1220",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Drug discovery in focal and segmental glomerulosclerosis

AU - Pullen, Nick

AU - Fornoni, Alessia

PY - 2016

Y1 - 2016

N2 - Despite the high medical burden experienced by patients with focal segmental glomerulosclerosis, the etiology of the condition remains largely unknown. Focal segmental glomerulosclerosis is highly heterogeneous in clinical and morphologic manifestations. While this presents challenges for the development of new treatments, research investments over the last 2 decades have yielded a surfeit of potential avenues for therapeutic intervention. The development of many of those ideas and concepts into new therapies, however, has been very disappointing. Here, we describe some of the factors that have potentially contributed to the poor translational performance from this research investment, including the confidence we ascribe to a target, the conduct of experimental studies, and the availability of selective reagents to test hypotheses. We will discuss the significance of genetic and systems traits as well as other methods for reducing bias. We will analyze the limitations of a successful drug development. We will use specific examples hoping that these will guide a consensus for investment and drive greater translational quality. We hope that this substrate will serve to exemplify the tremendous opportunity for intervention as well as facilitate greater collaborative effort between industry, academia, and private foundations in promoting appropriate validation of these targets. Only then will we have achieved our goal for curative therapies for this devastating disease.

AB - Despite the high medical burden experienced by patients with focal segmental glomerulosclerosis, the etiology of the condition remains largely unknown. Focal segmental glomerulosclerosis is highly heterogeneous in clinical and morphologic manifestations. While this presents challenges for the development of new treatments, research investments over the last 2 decades have yielded a surfeit of potential avenues for therapeutic intervention. The development of many of those ideas and concepts into new therapies, however, has been very disappointing. Here, we describe some of the factors that have potentially contributed to the poor translational performance from this research investment, including the confidence we ascribe to a target, the conduct of experimental studies, and the availability of selective reagents to test hypotheses. We will discuss the significance of genetic and systems traits as well as other methods for reducing bias. We will analyze the limitations of a successful drug development. We will use specific examples hoping that these will guide a consensus for investment and drive greater translational quality. We hope that this substrate will serve to exemplify the tremendous opportunity for intervention as well as facilitate greater collaborative effort between industry, academia, and private foundations in promoting appropriate validation of these targets. Only then will we have achieved our goal for curative therapies for this devastating disease.

KW - focal segmental glomerulosclerosis

KW - podocyte

KW - proteinuria

UR - http://www.scopus.com/inward/record.url?scp=84978120358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978120358&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2015.12.058

DO - 10.1016/j.kint.2015.12.058

M3 - Review article

C2 - 27165834

AN - SCOPUS:84978120358

VL - 89

SP - 1211

EP - 1220

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 6

ER -